{"id":"753e5a5f-b778-53e5-8c1f-dca7109c4516","stable_key":"220adaab-10d8-5c4e-a3f5-a48700ea794d:agmatine-sulfate-human-i1-binding","predicate":"binds","statement":"Agmatine bound human platelet I1 sites with high- and low-affinity components and preferential affinity for the high-affinity I1 component over tested alpha-2 subtypes.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"e3547baa-06fc-5c3a-bb07-971ac0c1f35b","mechanism_event_label":"A pharmacological binding site is recorded without inventing its molecular identity.","subject":{"id":"e2f83eb4-99ed-5050-87d3-3e4701d05c1a","slug":"agmatine","display_name":"Agmatine","entity_type_key":"small_molecule"},"object":{"id":"7a0c6282-480c-5ff3-a2de-c018d47f5eab","slug":"human-platelet-imidazoline-i1-sites","display_name":"Human platelet imidazoline I1 binding sites","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e3547baa-06fc-5c3a-bb07-971ac0c1f35b","stable_key":"220adaab-10d8-5c4e-a3f5-a48700ea794d:agmatine-sulfate-human-i1-binding-event","event_type":"observed_relationship","label":"A pharmacological binding site is recorded without inventing its molecular identity.","description":"Agmatine bound human platelet I1 sites with high- and low-affinity components and preferential affinity for the high-affinity I1 component over tested alpha-2 subtypes.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e2f83eb4-99ed-5050-87d3-3e4701d05c1a","slug":"agmatine","display_name":"Agmatine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"7a0c6282-480c-5ff3-a2de-c018d47f5eab","slug":"human-platelet-imidazoline-i1-sites","display_name":"Human platelet imidazoline I1 binding sites","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"ae2dddf4-ce04-57e3-8a06-7ed9fdc24554","slug":"agmatine-sulfate","display_name":"Agmatine Sulfate","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human platelet membrane radioligand competition.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Binding alone does not establish agonist efficacy, receptor sequence or clinical blood-pressure effects.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Agmatine Sulfate collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"agmatine-sulfate","display_name":"Agmatine Sulfate","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A pharmacological binding site is recorded without inventing its molecular identity.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. · 1995 · https://pubmed.ncbi.nlm.nih.gov/7853171/","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"eb31b1ea-1289-52bb-95d6-a56e7683b291","evidence_kind":"source_excerpt","locator":"Lines 284-290","start_line":284,"end_line":290,"excerpt":"## agmatine-sulfate-human-i1-binding\nA pharmacological binding site is recorded without inventing its molecular identity.\nAgmatine bound human platelet I1 sites with high- and low-affinity components and preferential affinity for the high-affinity I1 component over tested alpha-2 subtypes.\nModel: Human platelet membrane radioligand competition.\nLimitations: Binding alone does not establish agonist efficacy, receptor sequence or clinical blood-pressure effects.\nEvidence access: Primary abstract\nComparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. · 1995 · https://pubmed.ncbi.nlm.nih.gov/7853171/","model_system":"Human platelet membrane radioligand competition.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e0426971-7d13-51c9-8354-6547b664f1cf","stable_key":"import-220adaab-10d8-5c4e-a3f5-a48700ea794d","title":"Agmatine Sulfate: transport, guanidino metabolism, ion channels and cross-nutrient mechanisms (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"b55d70e22d07b80964f825770d92fdd1745221420ed8af8d94ca5182b9994509","revision_id":"fc7be029-20e0-5943-b74e-3b06ba694571","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}